Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Advancing Prevention of Pulmonary Fibrosis (APPLe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04564183
Recruitment Status : Not yet recruiting
First Posted : September 25, 2020
Last Update Posted : November 6, 2020
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:

This study plans to learn more about pulmonary fibrosis and how it develops. We want to understand if the disease can be found early, before the lung is permanently scarred.

This study will create a cohort, or group, of participants who are not currently diagnosed with pulmonary fibrosis, but who all have family members with pulmonary fibrosis. The cohort will allow us to learn how pulmonary fibrosis develops, and to learn how the lungs change over time in people with and without pulmonary fibrosis.


Condition or disease Intervention/treatment
IPF Pulmonary Fibrosis ILD Other: Sample collection Other: Questionnaires Radiation: High resolution CT scan of the chest Diagnostic Test: Pulmonary Function Test

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Advancing Prevention of Pulmonary Fibrosis - A Cohort Study of Preclinical Pulmonary Fibrosis
Estimated Study Start Date : December 1, 2020
Estimated Primary Completion Date : October 1, 2024
Estimated Study Completion Date : December 30, 2025

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Full Cohort
Entire study population
Other: Sample collection
Blood, Urine, Nail, Hair, Buccal Brush

Other: Questionnaires
SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire

Radiation: High resolution CT scan of the chest
All patients will undergo single prone volumetric thoracic chest CT scans performed at full inspiration using a 64-slice CT scanner at baseline.

Diagnostic Test: Pulmonary Function Test
All recruited subjects will complete measurements of pre-bronchodilator spirometry and a measurement of diffusion capacity in accordance with ATS guidelines. Exercise capacity will be assessed by performing a 6-minute walk test, according to ATS guidelines.

Sub-Cohort
Randomly selected sub-cohort from the larger group of all participants
Other: Sample collection
Blood, Urine, Nail, Hair, Buccal Brush

Other: Questionnaires
SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire

Radiation: High resolution CT scan of the chest
All patients will undergo single prone volumetric thoracic chest CT scans performed at full inspiration using a 64-slice CT scanner at baseline.

Diagnostic Test: Pulmonary Function Test
All recruited subjects will complete measurements of pre-bronchodilator spirometry and a measurement of diffusion capacity in accordance with ATS guidelines. Exercise capacity will be assessed by performing a 6-minute walk test, according to ATS guidelines.




Primary Outcome Measures :
  1. Screen all subjects for early Idiopathic Pulmonary Fibrosis (IPF) with High Resolution CT Scan of the Chest [ Time Frame: Baseline ]
    All subjects will be screened with a high resolution CT scan to identify early signs of lung fibrosis. CT scans will be evaluated by study radiologists.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
We will enroll up to 1,000 participants who are in families with two or more reported cases of pulmonary fibrosis.
Criteria

Inclusion Criteria:

  • First degree relative from Familial Interstitial Pneumonia families (two or more family members with IIP)
  • Age at least 40 years old and younger than 90 years old

Exclusion Criteria:

  • Diagnosed with known (physician-diagnosed) pulmonary fibrosis prior to informed consent
  • Other genetic diseases associated with interstitial lung disease
  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04564183


Contacts
Layout table for location contacts
Contact: Rachel Warren 303-724-8569 rachel.warren@cuanschutz.edu
Contact: Avram Walts avram.walts@cuanschutz.edu

Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: David Schwartz, MD University of Colorado School of Medicine
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT04564183    
Other Study ID Numbers: 20-1739
First Posted: September 25, 2020    Key Record Dates
Last Update Posted: November 6, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases